ARTICLE | Clinical News
Qinprezo vosaroxin regulatory update
January 11, 2016 8:00 AM UTC
EMA accepted for review an MAA from Sunesis for Qinprezo vosaroxin to treat relapsed acute myelogenous leukemia (AML) in patients ages >=60. The quinolone derivative intercalates DNA and inhibits topoisomerase II (TOP2). ...